The geneTIGA Consortium gathered in Berlin on 11-12 February 2026 for its Third Annual Meeting, bringing together partners from across Europe for two days of scientific presentations, strategic discussions, and collaborative planning. As the project enters its final year, the meeting provided a crucial opportunity to align on progress, refine priorities, and strengthen the collective effort toward advancing IgA receptor–based therapies and next‑generation gene editing technologies.
Day 1 – Scientific Progress and Collaboration
The meeting opened with presentations on IgA receptor innovation, next‑generation gene editing, and cross‑WP collaboration. Partners shared advances in receptor characterization, AI‑supported design tools, and improved genome‑editing safety strategies.
Key project milestones were confirmed, including lead candidate prioritization, final‑year strategy alignment, and preparations for future clinical studies in B‑cell malignancies and IgA nephropathy.
Day 2 – Patient Engagement and Translational Readiness
Consortium updates covered GMP readiness, IND preparation, advanced model systems, and IgA glycosylation research, reinforcing the project’s progress toward clinical translation. A central moment of Day 2 was the WP7 patient engagement session by European Kidney Patients’ Federation (EKPF), highlighting how patient perspectives shape trial design, communication needs, and meaningful outcomes.
The two‑day meeting reaffirmed the consortium’s commitment to scientific excellence, patient‑centered development, and collaborative innovation. With strong progress across scientific, regulatory, and engagement activities, geneTIGA is well‑positioned to advance toward its final‑year objectives and prepare for future clinical translation.
Comments are closed.